Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 5/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 5/20 | 1.00 |
| ▸ | GLA | P06280 | 5/20 | 1.00 |
| ▸ | GANC | Q8TET4 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 0.93 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.93 |
| ▸ | GBA1 | P04062 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14654237 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL1479404 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL2265529 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL2265531 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL9379987 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL1879685 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL20466285 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL7824407 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL7811568 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL18271004 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024069235-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2024-04-04 | — | — | WO | claimed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | claimed |
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CENTOGENE IP GMBH (DE) | 2021-07-29 | — | — | US | claimed |
| EP-2793872-B1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | CENTOGENE IP GMBH (DE) | 2021-03-10 | — | — | EP | claimed |
| EP-1896083-B1 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN AND DERIVATIVES | AMICUS THERAPEUTICS INC (US) | 2016-03-02 | — | — | EP | claimed |
| US-20160051528-A1 | Method for the Treatment of Pompe Disease Using 1-Deoxynojirimycin Derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2016-02-25 | — | — | US | claimed |
| EP-2932982-A1 | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives | Amicus Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| US-20150258081-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | CENTOGENE IP GMBH (DE) | 2015-09-17 | — | — | US | claimed |
| EP-2793872-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | Centogene IP GmbH (DE) | 2014-10-29 | — | — | EP | claimed |
| WO-2013091897-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | CENTOGENE GMBH (DE) | 2013-06-27 | — | — | WO | claimed |
| US-20110070643-A1 | Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics | AMICUS THERAPEUTICS, INC. | 2011-03-24 | — | — | US | claimed |
| WO-2010138608-A1 | UTILIZATION OF PHARMACOLOGICAL CHAPERONES TO IMPROVE MANUFACTURING AND PURIFICATION OF BIOLOGICS | AMICUS THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | claimed |
| US-7514453-B2 | Preventing degradation of mutant enzymes associated with lysosomal storage diseases in mammalian cells | AMICUS THERAPEUTICS INC. (US) | 2009-04-07 | — | — | US | claimed |
| EP-1896083-A2 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN AND DERIVATIVES | Amicus Therapeutics, Inc. (US) | 2008-03-12 | — | — | EP | claimed |
| US-20070021381-A1 | Stabilizing the mutant enzyme by administering a reversible competitive inhibitor consisting an iminosugar, 4-epi-isofagomine or 1-deoxygalactonojirimycin; Gaucher's disease; lysosomal storage diseases | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2007-01-25 | — | — | US | claimed |
| US-20060264467-A1 | Method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-11-23 | — | — | US | claimed |
| WO-2006125141-A2 | A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2006-11-23 | — | — | WO | claimed |
| US-6774135-B2 | 1-DEOXY-GALACTONOJIRIMYCIN AND RELATED COMPOUNDS USED TO TREAT FABRY DISEASE | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2004-08-10 | — | — | US | claimed |
| US-6589964-B2 | Administering a competitive inhibitor of the enzyme in an amount effective to enhance enzyme activtiy, selected from 2,5-dideoxy- 2,5-imino-D-mannitol, 3,4-diepi- alpha -homonojirimycin, 5-O- deoxyglactonojirimycin, calystegines | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-07-08 | — | — | US | claimed |
| US-6583158-B1 | Competitive inhibitors of the enzymes, in particular imino sugars and related compounds | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CMA1, MAN2B1, GBA3 | MGAM 674/4885FUCA1 113/4885GLA 45/4885 |
| US-20160051528-A1 | Method for the Treatment of Pompe Disease Using 1-Deoxynojirimycin Derivatives | GAA, MAN2B1, MAN1B1 | MGAM 10/4885FUCA1 89/4885GLA 76/4885 |
| US-20060264467-A1 | Method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives | GAA, MAN2B1, MAN1B1 | MGAM 10/4885FUCA1 74/4885GLA 85/4885 |
| US-20070021381-A1 | Stabilizing the mutant enzyme by administering a reversible competitive inhibitor consisting an iminosugar, 4-epi-isofagomine or 1-deoxygalactonojirimycin; Gaucher's disease; lysosomal storage diseases | GBA1, GBA2, GALC | MGAM 11/4885FUCA1 42/4885GLA 24/4885 |
| US-20150258081-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | MAN2B1, CMA1, GBA1 | MGAM 221/4885FUCA1 56/4885GLA 51/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | MGAM 25/4885FUCA1 15/4885GLA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.